As the largest publicly traded U.S. healthcare enterprise, Eli Lilly & Co. (NYSE:LLY) has historically offered investors a reliable avenue for growth. Indeed, this narrative has been particularly powerful in 2023 and 2024, which saw LLY stock rise from around $360 to approximately$960 in late summer of last year. However, amid a challenging environment in healthcare, LLY presents both opportunities and risks.Fundamentally, Eli Lilly represents a juggernaut in medical innovations. Recently, the company has ...